Nissan Chemical Industries, Ltd. Reports Positive Phase IIb Study Results For NM-702 In Intermittent Claudication  
3/13/2006 11:16:37 AM

LOS ANGELES--(BUSINESS WIRE)--March 13, 2006--Nissan Chemical Industries, Ltd. (Nissan Chemical), announced today positive results of their Phase IIb study NCI-IC-0201 of NM-702 for the treatment of intermittent claudication. The study enrolled 391 patients, who were assessed after six months of therapy. Results from the study showed NM-702 was associated with a statistically significant increase in patients' Peak Walking Time as compared with placebo, the study's primary endpoint. Secondary endpoints were also supportive of NM-702 efficacy.